About K2 HealthVentures
K2 HealthVentures, established in 2018, is a private debt fund primarily based in Boston, United States. It specializes in financing Conventional Debt round of companies based in United States. Its portfolio includes 43 firms, spanning the Life Sciences, HealthTech sectors.
As of Aug 2026, K2 HealthVentures has 3 unicorns under its belt and has witnessed 18 portfolio exits so far. Its most notable investments include companies like TScan Therapeutics, Alto Neuroscience and DispatchHealth.
Its latest investment was a $53M Series D round in Hopscotch Health on Aug 18, 2026, which also saw participation from 8VC and Town Hall Ventures.
Key Metrics
Founded Year
2018
Location
Boston, United States
Portfolio Companies
Sectors of Investment
Stages of Investment
Conventional Debt, Series D & 7 more
Locations of Investment
Unicorn in Portfolio
K2 HealthVentures' List of Top Investments
K2 HealthVentures has a portfolio of 43 companies, including 3 unicorns. Their most notable investments include TScan Therapeutics and Alto Neuroscience.Their portfolio spans across United States, Ireland, Singapore and 1 more locations. They have invested in Life Sciences, HealthTech, Enterprise Applications and 7 other sectors, across stages such as Conventional Debt, Series D and 7 more. Here is the list of top investments by K2 HealthVentures:_1556184640480.png?format=webp&height=120&width=120){kind=logo}
Developer of T cell therapies to harness the immune system against cancer. The company focuses on hematologic malignancies and solid tumors using proprietary platforms like TargetScan and ReceptorScan. The company's product line include TSC-100 and TSC-101 target residual disease in AML, MDS, and ALL patients post-allogeneic hematopoietic cell transplant.
Key facts about TScan Therapeutics
- Founded Year: 1995
- Location: Boston (United States)
- Annual Revenue: $10M - $50M as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $180M
- Employee Count: 151 as on Jun 30, 2026
- Investors: RA Capital Management, Bessemer Venture Partners and 9 Others
- Latest Funding Round: Series C, Jan 25, 2021, $*****
- Highlight: Public
AI-driven drug discovery platform for neurological diseases based on patients biomarkers. The company's platform measures patients biomarkers like EEG and wearable data, behavioral patterns, genetics, and other factors to develop personalized psychiatric drugs. The company has pipeline of drugs including ALTO-100 for depression, ALTO-101 for neurodegenerative diseases, and more.
Key facts about Alto Neuroscience
- Founded Year: 2019
- Location: San Francisco (United States)
- Stage: Public
- Total Funding till date: $145M
- Employee Count: 87 as on Jun 30, 2026
- Investors: Point72, Commodore Capital and 36 Others
- Latest Funding Round: Post IPO, Mar 16, 2026, $*****
- Highlight: Public
Provider of on-demand physician visits at home. The platform provides access to users to request physicians visit based on symptoms and conditions. It offers prescription delivery with insurance claims. The platform offers treatments for multiple health conditions.
Key facts about DispatchHealth
- Founded Year: 2013
- Location: Denver (United States)
- Valuation: $*****
- Stage: Series D
- Total Funding till date: $700M
- Employee Count: 979 as on Jun 30, 2026
- Investors: Adams Street Partners, Pegasus Tech Ventures and 15 Others
- Latest Funding Round: Series D, Oct 31, 2022, $*****
- Highlight: Editors' Pick
Developer of mineral-based sunscreens and clinical skincare products. It offers a range of sunscreens, treatments, serums, and cosmetics formulated with natural minerals and botanicals. The company focuses on providing effective sun protection and skin health improvement through clinically tested products. Product lines include mineral sunscreens, skincare treatments addressing concerns like aging and hyperpigmentation, and mineral-based cosmetics. A skin quiz is available to assist customers in selecting personalized skincare regimens.
Key facts about Colorescience
- Founded Year: 2000
- Location: Carlsbad (United States)
- Stage: Acquired
- Total Funding till date: $70M
- Employee Count: 132 as on Jun 30, 2026
- Investors: Aisling Capital, Domain Associates and 10 Others
- Latest Funding Round: Conventional Debt, Sep 14, 2020, $*****
- Highlight: Acquired
Provider of mobile apps for treatment of brain disorders. It offers solutions to treat people with brain disorders and neuro psychiatric dysfunction. The platform enables patients to input daily activity and aims for behavior and cognitive modification, by connecting with the care team. The mobile apps are focused on smoking and cessation, Alzheimers, ADHD, and TBI.
Key facts about Click Therapeutics
- Founded Year: 2012
- Location: New York City (United States)
- Stage: Series D
- Total Funding till date: $180M
- Employee Count: 105 as on Jun 30, 2026
- Investors: Accelmed, The Private Shares Fund and 15 Others
- Latest Funding Round: Series D, Apr 09, 2026, $*****
- Highlight: Editors' Pick
K2 HealthVentures' Year-on-Year Investment Trends
K2 HealthVentures has invested in 43 companies over the last 7 years, with an average of 3 new investments annually in the last 5 years. In 2025, it made 3 investments, while as of Aug 2026, it has made 5 investments in this year. Its most recent first time investment was in Hopscotch Health and most recent follow-on round was in Vedanta Biosciences.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 5 | 0 | 5 |
2025 | 3 | 0 | 3 |
2024 | 1 | 1 | 2 |
2023 | 4 | 1 | 5 |
2022 | 1 | 1 | 2 |
2021 | 3 | 2 | 5 |
2020 | 5 | 0 | 5 |
2019 | 1 | 0 | 1 |
K2 HealthVentures' Investments by Stage
K2 HealthVentures has made 10 investments in Conventional Debt stage with an average round size of $49.8M, 3 investments in Series D stage with an average round size of $108M and 2 investments in Post IPO stage with an average round size of $22.5M.Stage of entry | No. of Investments |
|---|---|
Conventional Debt | 10 |
Series D | 3 |
Post IPO | 2 |
Series B | 2 |
Venture Debt | 2 |
Others | 4 |
Note: We have considered here, only first round of investments
K2 HealthVentures' Investments by Sector
K2 HealthVentures has a diverse portfolio, with companies operating in the Life Sciences, HealthTech, Healthcare, Enterprise Applications and Consumer. Notably, it has invested in 32 Tech companies, 28 Enterprise (B2B) companies, 8 Software companies and at least 7 companies focusing on Consumer (B2C).Sector | No. of Investments |
|---|---|
Life Sciences | 9 |
HealthTech | 7 |
Healthcare | 5 |
Enterprise Applications | 4 |
Consumer | 3 |
Others | 8 |
Note: We have considered here, only first round of investments
K2 HealthVentures' Investments by Geography
K2 HealthVentures has made most investments in United States (21), followed by Singapore where it has made 1 investment.Country | No. of Investments |
|---|---|
United States | 21 |
Singapore | 1 |
Note: We have considered here, only first round of investments
K2 HealthVentures' recent investments
K2 HealthVentures has made 5 investments in 2026 so far. Hopscotch Health and Mighty Therapeutics are the latest among them.Here are the most recent investments by K2 HealthVentures:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Aug 18, 2026 | United States | Series D | 2683 | [+7] | |
Jul 14, 2026 | United States | Conventional Debt | 6156 | - | |
Feb 26, 2026 | United States | Series D | 1213 | [+4] | |
Jan 21, 2026 | - | Series A | 2157 | [+1] | |
Jan 08, 2026 | United States | Series B | 6644 | [+7] |
Unicorns in K2 HealthVentures' Portfolio
K2 HealthVentures has 3 unicorns in its portfolio - DispatchHealth, LetsGetChecked and Inari. The most recent unicorn in their portfolio is DispatchHealth. It became a unicorn in 2022.Here is a list of unicorns in K2 HealthVentures' portfolio:
Tracxn Score | Company | Short Description | Founded year | Sector | Location | Company Stage | First Investment/ Acquisition Details |
|---|---|---|---|---|---|---|---|
65 | Provider of on-demand physician visits at home | 2013 | Denver | Series D | {rnksjp | ||
56 | Online platform to order at home diagnostic tests for all health conditions | 2013 | Dublin | Series D | vyxyptt | ||
64 | Developer of technology to improve crop breeding and seed production | 2016 | Cambridge | Series G | zlvvgwz |
IPOs and Publicly Listed companies in K2 HealthVentures' Portfolio
11 of K2 HealthVentures' portfolio companies have become public. Alto Neuroscience got listed on the New York Stock Exchange (NYSE), in Feb 2024 at marketcap of $409M and TScan Therapeutics got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ) at marketcap of $359M.Here are K2 HealthVentures' portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Feb 02, 2024 | Jan 30, 2023 | Venture Debt | 2022 | |
Jul 16, 2021 | - | - | 9133 | |
Jun 25, 2021 | - | - | 4631 | |
Apr 27, 2021 | - | - | 3594 | |
Mar 26, 2021 | - | - | 1205 |
_1556184640480.png?devicePixelRatio=2&height=20&width=20){kind=logo}
Acquired companies in K2 HealthVentures' Portfolio
7 companies from K2 HealthVentures' portfolio have been acquired. The most recent acquisition was 89bio in Sep 2025 by Roche for $*****.Here are K2 HealthVentures' portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Sep 17, 2025 | - | - | 1986 | |
May 16, 2025 | - | - | 2583 | |
Jan 08, 2024 | Mar 28, 2023 | Post IPO | 6217 | |
Jun 16, 2023 | - | - | 3975 | |
Aug 12, 2020 | Jan 10, 2020 | Conventional Debt | 7046 |
Team profile of K2 HealthVentures
K2 HealthVentures has a team of 11 members including 2 Partners and 2 Principals located in United States.Here is a list of top team members in K2 HealthVentures:
Name | Designation | Location | Contact Details |
|---|---|---|---|
Partner | Miami | - | |
Partner | Chicago | ||
Principal | New York City | ||
Principal | New York City |
Co-investors of K2 HealthVentures
Over the past 7 years, 257 investors have co-invested in K2 HealthVentures's portfolio companies. This includes funds and angels.
- Invested before K2 HealthVentures: HHS, Oak HC/FT and 163 others have invested in rounds before K2 HealthVentures. There are 3 companies where HHS has invested before K2 HealthVentures and 3 companies where Oak HC/FT has invested before K2 HealthVentures.
- Top Co-investors of K2 HealthVentures: 49 investors entered a company along with K2 HealthVentures. These include investors like Rubicon Founders (3 companies).
- Invested after K2 HealthVentures: A total of 43 investors have invested in K2 HealthVentures's portfolio after their investments. Top Investors include Alexandria (2 companies) and Commodore Capital (2 companies).
Recent News related to K2 HealthVentures
•
Hopscotch Primary Care Secures $53 Million in Series D Funding to Expand Rural Healthcare AccessPR Newswire•Aug 18, 2026•Hopscotch Health, Town Hall Ventures, 8VC, K2 HealthVentures and 2 others
•
Mighty Therapeutics Secures Up to $125MM from K2 HealthVenturesABFJournal•Jul 16, 2026•K2 HealthVentures, Mighty Therapeutics
•
Cartesian Therapeutics Secures up to $150 Million in Non-Dilutive FinancingGlobeNewswire•May 26, 2026•K2 HealthVentures, Cartesian Therapeutics, Cartesian
•
Honest Health Raises $140M, Plans Market and Partnership ExpansionsNashville Post•Feb 26, 2026•K2 HealthVentures, Rubicon Founders, NewSpring, Honest Health and 3 others
•
Zarminali Pediatrics Raises $110M Series A To Transform American Pediatric Careintelligence360•Feb 09, 2026•Zarminali, Healthier Capital, K2 HealthVentures, General Catalyst and 9 others
•
•
Apella Secures $80M to Scale Ambient Video Intelligence Across Surgical SuiteHIT Consultant•Jan 08, 2026•Apella, Vensana Capital, K2 HealthVentures, Houston Methodist and 5 others
•
Phil Receives $60 Million Debt Financing from K2 HealthVenturessvdaily.com•Jul 14, 2025•K2 HealthVentures, Phil
•
Phil scores $60M in growth debt financing and more digital health fundingMobiHealthNews•Jul 10, 2025•K2 HealthVentures, Phil
•
